SCHEMBL2362843

SCHEMBL2362843

COc1cc(CS(C)(=O)=O)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.48
ALPL P05186 1/20 0.38
CYP1A1 P04798 2/20 0.36
HTR2A P28223 1/20 0.36
ERBB2 P04626 1/20 0.34
BRD4 O60885 2/20 0.34
P2RY2 P41231 2/20 0.32
P2RY4 P51582 2/20 0.32
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2D6 P10635 2/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362967 0.86 CYP3A4 (0.50) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL3314215 0.85 CYP3A4 (0.45) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2363467 0.85 CYP3A4 (0.43) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2363082 0.85 HTR2A (0.44) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2348091 0.84 CYP3A4 (0.51) CYP3A4ALPLCYP1A1HTR2ATP53
SCHEMBL3312623 0.83 CYP3A4 (0.44) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL3314903 0.83 CYP3A4 (0.44) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL3308904 0.83 CYP3A4 (0.42) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2362428 0.83 CYP3A4 (0.44) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2362488 0.83 HTR2A (0.54) CYP3A4CYP1A1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO claimed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885ALPL 4328/4885CYP1A1 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.